Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates that glucocorticoids directly suppress insulin biosynthesis in pancreatic beta cells, suggesting GR and JNK inhibition may prevent steroid-induced diabetes.
Glucocorticoids induce hyperglycemia by promoting hepatic gluconeogenesis and impairing insulin sensitivity in peripheral tissues. However, their direct effects on pancreatic β-cells remained poorly understood. This study investigated whether glucocorticoids directly impair insulin biosynthesis in pancreatic β-cells, using both in vivo and in vitro models. In vivo, male C57BL/6J mice were treated with vehicle, corticosterone, or dexamethasone in drinking water for two weeks. Pancreatic β-cell line MIN6 cells were treated with and without a glucocorticoid receptor (GR) antagonist RU-486 or a JNK inhibitor SP600125. GR knockdown was also performed using siRNA. In vivo, dexamethasone, but not corticosterone, induced hyperglycemia and insulin resistance, while both corticosterone and dexamethasone reduced high-quality insulin granules and suppressed the expression of insulin biosynthesis-related genes in pancreatic islets. In vitro, dexamethasone decreased the expression of Ins1, Ins2, Pdx1, and Mafa, and significantly reduced glucose-stimulated insulin secretion (GSIS). RU-486, SP600125, or GR knockdown ameliorated these impairments. Electron microscopy showed the reduction of insulin granule density in dexamethasone-treated cells, which was preserved by GR or JNK inhibition. Glucocorticoids directly suppress insulin biosynthesis in pancreatic β-cells via GR signaling despite preserved or enhanced glucose-stimulated insulin secretion in vivo. It is likely that inhibition of GR/JNK signaling may represent a potential strategy to protect β-cells from steroid-induced dysfunction.
No takes yet. Share an insight, caveat, or question.
Iwamoto et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: